カテゴリ： GlobalData, アメリカ, 企業調査

Aduro BioTech Inc (ADRO)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Aduro BioTech Inc (ADRO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C12380
◆発行会社（調査会社）：GlobalData
◆発行日：2018年12月
◆ページ数：80
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Aduro BioTech Inc (Aduro BioTech) is a clinical-stage immunotherapy company that discovers, develops and commercializes therapies for the treatment of cancer. The company develops product candidates using proprietary technology platforms such as live, attenuated, double-deleted listeria, sting pathway activators; and B-select monoclonal antibodies to create immunotherapies for the treatment of cancers, infectious and autoimmune diseases. Its products under development are intended for the treatment of multiple indications, including pancreatic, lung, ovarian, prostate cancers, mesothelioma and glioblastoma. The company collaborates with various pharmaceutical companies to expand its products and technology platforms. Aduro BioTech is headquartered in Berkeley, California, the US.

Aduro BioTech Inc (ADRO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aduro BioTech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Aduro BioTech Acquires GVAX Assets From BioSante Pharma 13
Venture Financing 15
Aduro BioTech Raises USD51.4 Million in Series D Venture Financing 15
Aduro BioTech Raises USD55 Million in Series C Financing 17
Aduro BioTech Raises US$7 Million In Venture Financing 18
Aduro BioTech Raises US$6.5 Million In Venture Financing 19
BioNovion Raises Funds through Venture Financing 20
Partnerships 21
Aduro BioTech Enters into Agreement with Immunotherapeutics and Vaccine Research Initiative 21
HitGen Enters into Agreement with Aduro Biotech 22
Aduro Biotech Expands Agreement with Merck 23
University of California, Berkeley Enters into Agreement with Aduro Biotech 24
Aduro Biotech Enters into Agreement with Novartis for Immuno-Oncology Products 25
BioNovion Enters into Agreement with Genmab to Discover and Develop Multiple Bispecific Antibody Products 26
Aduro BioTech Enters Into Co-Development Agreement With Protein Potential And Sanaria To Develop Malaria Vaccines 27
Licensing Agreements 29
Aduro BioTech Enters into Licensing Agreement with Stanford University 29
Aduro BioTech Amends Licensing Agreement with University of California, Berkeley 30
Merck Enters into Licensing Agreement with BioNovion 31
Aduro BioTech Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center, Rockefeller University, Rutgers and University of Bonn 32
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech 34
Aduro BioTech Enters Into Licensing Agreement With University Of California, Berkeley 35
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech for GVAX technology 36
Aduro BioTech Enters into Licensing Agreement with Johns Hopkins University for GVAX-Related Patent Rights 37
Aduro BioTech Enters into Licensing Agreement with Karagen Pharma 38
Aduro BioTech Enters into Licensing Agreement with UCB 39
Equity Offering 40
Aduro Biotech Plans to Raise Funds through Public Offering of Shares 40
Aduro Biotech Plans to Raise up to USD100 Million in Public Offering of Shares 41
Aduro Biotech to Raise up to USD100 Million in Public Offering of Shares 42
Aduro BioTech Raises USD25 Million in Private Placement Shares 43
Aduro BioTech Raises USD136.8 Million in IPO 44
Acquisition 46
Aduro Biotech Acquires BioNovion 46
Aduro BioTech Inc – Key Competitors 47
Aduro BioTech Inc – Key Employees 48
Aduro BioTech Inc – Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Recent Developments 50
Financial Announcements 50
Oct 30, 2018: Aduro Biotech reports third quarter 2018 financial results 50
Aug 01, 2018: Aduro Biotech reports second quarter 2018 financial results 51
May 02, 2018: Aduro Biotech Announces First Quarter 2018 Financial Results 52
Mar 01, 2018: Aduro Biotech Reports Fourth Quarter And Full Year 2017 Financial Results 53
Oct 31, 2017: Aduro Biotech Reports Third Quarter 2017 Financial Results 54
Aug 02, 2017: Aduro Biotech Reports Second Quarter 2017 Financial Results 55
May 02, 2017: Aduro Biotech Reports First Quarter 2017 Financial Results 56
Mar 01, 2017: Aduro Biotech Announces Fourth Quarter and Full Year 2016 Financial Results 57
Corporate Communications 59
Sep 19, 2018: Aduro Biotech Announces the Departure of Natalie R. Sacks 59
Jan 05, 2018: Aduro Biotech Announces Management Changes 60
Jul 27, 2017: Aduro Biotech Announces Andrea van Elsas, Ph.D., to be Named Chief Scientific Officer Effective September 1, 2017 61
Apr 20, 2017: Aduro Biotech Announces Management Promotions 62
Product News 63
12/18/2017: Aduro Biotech Announces the Initiation of a Phase 1/2 Clinical Trial of BION-1301, a Novel Anti-APRIL Antibody, for the Treatment of Multiple Myeloma 63
12/12/2017: Aduro Biotech Provides Update on CRS-207 Programs 64
09/04/2018: Aduro Biotech and Dana-Farber Cancer Institute publish data highlighting immunosuppressive impact of APRIL in multiple myeloma in leukemia 65
03/06/2017: Aduro Biotech Presents Data On BION-1301 at the 2017 American Association for Cancer Research Annual Meeting 66
03/06/2017: Aduro Biotech Presents Data on Vaccine Technology targeting STING at the 2017 American Association for Cancer Research Annual Meeting 67
Clinical Trials 68
Sep 04, 2018: Aduro Biotech presents preclinical data for BION-1301, a first-in-class antibody targeting human APRIL, at the 2018 European Congress of Immunology 68
Apr 17, 2018: Aduro Biotech Presents Preclinical Data of ADU-1604 at the American Association for Cancer Research Annual Meeting 69
Apr 17, 2018: Aduro Biotech Presents Preclinical Data of BION-1301 at the American Association for Cancer Research Annual Meeting 70
Mar 14, 2018: Aduro Biotech to Present Preclinical Data on ADU-1604 at AACR 2018 Annual Meeting 71
Mar 14, 2018: Aduro Biotech to Present Preclinical Data on BION-1301 at AACR 2018 Annual Meeting 72
Nov 10, 2017: Aduro Biotech Announces Promising Preclinical Data that Validate Anti-CTLA-4 Antibody ADU-1604 73
Nov 01, 2017: Aduro Biotech Announces Upcoming Data Presentations at the 59th American Society of Hematology Annual Meeting 74
Sep 27, 2017: Aduro Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Personalized Immunotherapy pLADD Based on Proprietary Neoantigen Technology 75
Aug 09, 2017: Aduro Biotech Bolsters Intellectual Property Position in STING Field with Two New Patents 76
Jun 29, 2017: Aduro Biotech Announces Initiation of Phase 2 Clinical Trial of CRS-207 in Combination with KEYTRUDA (pembrolizumab) for the Treatment of Previously-Treated Gastroesophageal Adenocarcinoma 77
Jun 28, 2017: Aduro Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of CRS-207 in Combination with KEYTRUDA for the Treatment of Patients with Previously Treated Malignant Pleural Mesothelioma 78
May 26, 2017: Aduro Biotech to Host and Webcast an Investor Event in Conjunction with the 2017 ASCO Annual Meeting 79
Appendix 80
Methodology 80
About GlobalData 80
Contact Us 80
Disclaimer 80

List of Tables
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aduro BioTech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aduro BioTech Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aduro BioTech Acquires GVAX Assets From BioSante Pharma 13
Aduro BioTech Raises USD51.4 Million in Series D Venture Financing 15
Aduro BioTech Raises USD55 Million in Series C Financing 17
Aduro BioTech Raises US$7 Million In Venture Financing 18
Aduro BioTech Raises US$6.5 Million In Venture Financing 19
BioNovion Raises Funds through Venture Financing 20
Aduro BioTech Enters into Agreement with Immunotherapeutics and Vaccine Research Initiative 21
HitGen Enters into Agreement with Aduro Biotech 22
Aduro Biotech Expands Agreement with Merck 23
University of California, Berkeley Enters into Agreement with Aduro Biotech 24
Aduro Biotech Enters into Agreement with Novartis for Immuno-Oncology Products 25
BioNovion Enters into Agreement with Genmab to Discover and Develop Multiple Bispecific Antibody Products 26
Aduro BioTech Enters Into Co-Development Agreement With Protein Potential And Sanaria To Develop Malaria Vaccines 27
Aduro BioTech Enters into Licensing Agreement with Stanford University 29
Aduro BioTech Amends Licensing Agreement with University of California, Berkeley 30
Merck Enters into Licensing Agreement with BioNovion 31
Aduro BioTech Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center, Rockefeller University, Rutgers and University of Bonn 32
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech 34
Aduro BioTech Enters Into Licensing Agreement With University Of California, Berkeley 35
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech for GVAX technology 36
Aduro BioTech Enters into Licensing Agreement with Johns Hopkins University for GVAX-Related Patent Rights 37
Aduro BioTech Enters into Licensing Agreement with Karagen Pharma 38
Aduro BioTech Enters into Licensing Agreement with UCB 39
Aduro Biotech Plans to Raise Funds through Public Offering of Shares 40
Aduro Biotech Plans to Raise up to USD100 Million in Public Offering of Shares 41
Aduro Biotech to Raise up to USD100 Million in Public Offering of Shares 42
Aduro BioTech Raises USD25 Million in Private Placement Shares 43
Aduro BioTech Raises USD136.8 Million in IPO 44
Aduro Biotech Acquires BioNovion 46
Aduro BioTech Inc, Key Competitors 47
Aduro BioTech Inc, Key Employees 48
Aduro BioTech Inc, Other Locations 49
Aduro BioTech Inc, Subsidiaries 49

List of Figures
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Aduro BioTech Inc (ADRO)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Bharat Heavy Electricals Limited (BHEL)：企業の戦略・SWOT・財務情報
    Bharat Heavy Electricals Limited (BHEL) - Strategy, SWOT and Corporate Finance Report Summary Bharat Heavy Electricals Limited (BHEL) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Hydro-Quebec-エネルギー分野：企業M&A・提携分析
    Summary Hydro-Quebec is a government-owned energy utility that generates, transmits and distributes electricity. The company specializes in renewable energy generation, using hydro sources and supports the development of electricity using other technologies such as wind energy and biomass. It genera …
  • Svenska Kraftnat：企業の戦略的SWOT分析
    Svenska Kraftnat - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Europcar Mobility Group SA (EUCAR)：企業の財務・戦略的SWOT分析
    Europcar Mobility Group SA (EUCAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Moss Bros Group Plc (MOSB)：企業の財務・戦略的SWOT分析
    Moss Bros Group Plc (MOSB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • W. R. Grace & Co：企業の戦略・SWOT・財務分析
    W. R. Grace & Co - Strategy, SWOT and Corporate Finance Report Summary W. R. Grace & Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Sinphar Pharmaceutical Co Ltd (1734)：企業の財務・戦略的SWOT分析
    Sinphar Pharmaceutical Co Ltd (1734) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Sonali Bank Limited：企業の戦略・SWOT・財務情報
    Sonali Bank Limited - Strategy, SWOT and Corporate Finance Report Summary Sonali Bank Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Mobidiag Ltd：医療機器：M&Aディール及び事業提携情報
    Summary Mobidiag Ltd (Mobidiag) is a biotechnology company that develops and markets products for molecular diagnosis of infectious diseases and test kits. The company's products include Novodiag, Amplidiag, and Prove-it. Its Amplidiag is a diagnostic test for high-volume screening of gastrointestin …
  • Technip SA (TEC)-石油・ガス分野：企業M&A・提携分析
    Summary Technip SA (Technip) is a provider of project management, engineering and construction services to energy sector. It offers a comprehensive portfolio of technologies and services for the subsea oil and gas developments to the largest and most complex offshore and onshore infrastructures. The …
  • Enercon Services Inc：電力：M&Aディール及び事業提携情報
    Summary Enercon Services, Inc. (Enercon) is a diversified consulting company offering architectural engineering, environmental, technical and management services. Its offerings include licensing, operations, permitting, construction, decommissioning, and staff augmentation, cyber security and regula …
  • Digital China Holdings Limited：企業の戦略・SWOT・財務情報
    Digital China Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Digital China Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Berry Global Group Inc：戦略・SWOT・企業財務分析
    Berry Global Group Inc - Strategy, SWOT and Corporate Finance Report Summary Berry Global Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Parity Group plc (PTY)：企業の財務・戦略的SWOT分析
    Summary Parity Group plc (Parity) is a technology company that offers professional recruitment, IT solutions and consultancy services. The company’s technology solutions include business intelligence, database analytics and development; IT consulting and application management support.The company pr …
  • Hyundai Rotem Co：企業の戦略・SWOT・財務分析
    Hyundai Rotem Co - Strategy, SWOT and Corporate Finance Report Summary Hyundai Rotem Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Baker Hughes Incorporated (BHGE)-石油・ガス分野：企業M&A・提携分析
    Summary Baker Hughes Incorporated (Baker Hughes), a subsidiary of General Electric Co is a provider of oil and gas equipment and services. The company is a supplier of oilfield services, products, technology and systems to oil and gas industry. It also offers industrial and other products and servic …
  • Weight Watchers International, Inc.：企業の戦略・SWOT・財務分析
    Weight Watchers International, Inc. - Strategy, SWOT and Corporate Finance Report Summary Weight Watchers International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • AKB Rosbank：企業の戦略・SWOT・財務情報
    AKB Rosbank - Strategy, SWOT and Corporate Finance Report Summary AKB Rosbank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Covance Inc：企業の戦略的SWOT分析
    Covance Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Basellandschaftliche Kantonalbank：企業の戦略・SWOT・財務分析
    Basellandschaftliche Kantonalbank - Strategy, SWOT and Corporate Finance Report Summary Basellandschaftliche Kantonalbank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆